{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:12:34Z","timestamp":1784693554704,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochirurgie"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuchi.2016.09.004","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T17:15:49Z","timestamp":1486142149000},"page":"370-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-9945","authenticated-orcid":false,"given":"S.","family":"Goutagny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1037-9707","authenticated-orcid":false,"given":"M.","family":"Kalamarides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.neuchi.2016.09.004_bib0190","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1080\/00016480310005101","article-title":"Expression of angiogenic growth factors in acoustic neurinoma","volume":"123","author":"Brieger","year":"2003","journal-title":"Acta Otolaryngol"},{"issue":"12","key":"10.1016\/j.neuchi.2016.09.004_bib0195","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/00005537-200312000-00014","article-title":"Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate","volume":"113","author":"Cay\u00e9-Thomasen","year":"2003","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.neuchi.2016.09.004_bib0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00129492-200501000-00017","article-title":"VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate","volume":"26","author":"Cay\u00e9-Thomasen","year":"2005","journal-title":"Otol Neurotol"},{"issue":"1","key":"10.1016\/j.neuchi.2016.09.004_bib0205","first-page":"30","article-title":"Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas","volume":"22","author":"Saito","year":"2003","journal-title":"Clin Neuropathol"},{"issue":"3","key":"10.1016\/j.neuchi.2016.09.004_bib0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11060-007-9336-0","article-title":"Expression of VEGF and its receptor genes in intracranial schwannomas","volume":"83","author":"Uesaka","year":"2007","journal-title":"J Neurooncol"},{"issue":"4","key":"10.1016\/j.neuchi.2016.09.004_bib0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.neuchi.2016.09.004_bib0220","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.neuchi.2016.09.004_bib0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy","volume":"126","author":"Eminowicz","year":"2012","journal-title":"J Laryngol Otol"},{"issue":"6","key":"10.1016\/j.neuchi.2016.09.004_bib0230","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"12","key":"10.1016\/j.neuchi.2016.09.004_bib0235","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"14","key":"10.1016\/j.neuchi.2016.09.004_bib0240","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.neuchi.2016.09.004_bib0245","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","article-title":"Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"272","author":"Farschtschi","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.neuchi.2016.09.004_bib0250","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/annonc\/mdr012","article-title":"Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab","volume":"22","author":"Goutagny","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.neuchi.2016.09.004_bib0255","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuchi.2016.09.004_bib0260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-015-1925-8","article-title":"Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab","volume":"125","author":"Essayed","year":"2015","journal-title":"J Neurooncol"},{"issue":"6","key":"10.1016\/j.neuchi.2016.09.004_bib0265","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ane.12490","article-title":"Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2","volume":"133","author":"Farschtschi","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.neuchi.2016.09.004_bib0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J Neurooncol"},{"issue":"6","key":"10.1016\/j.neuchi.2016.09.004_bib0275","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","article-title":"Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients","volume":"73","author":"Slusarz","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.neuchi.2016.09.004_bib0280","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00280-016-3046-2","article-title":"Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2","volume":"77","author":"Ouerdani","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.neuchi.2016.09.004_bib0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/159101991201800201","article-title":"Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of bevacizumab for the treatment of vestibular schwannomas in neurofibromatosis type 2","volume":"8","author":"Riina","year":"2012","journal-title":"Interv Neuroradiol"},{"key":"10.1016\/j.neuchi.2016.09.004_bib0290","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.neuchi.2016.09.004_bib0295","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00129492-200409000-00024","article-title":"Correlation of growth factor receptor expression with clinical growth in vestibular schwannomas","volume":"25","author":"OReilly","year":"2004","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.neuchi.2016.09.004_bib0300","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J Cell Bio"},{"issue":"4","key":"10.1016\/j.neuchi.2016.09.004_bib0305","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/MCB.01139-07","article-title":"Localization to the cortical cytoskeleton is necessary for Nf2\/merlin-dependent epidermal growth factor receptor silencing","volume":"28","author":"Cole","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.neuchi.2016.09.004_bib0310","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/onc.2008.427","article-title":"Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas","volume":"28","author":"Lallemand","year":"2009","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.neuchi.2016.09.004_bib0315","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"issue":"8","key":"10.1016\/j.neuchi.2016.09.004_bib0320","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol"},{"issue":"9","key":"10.1016\/j.neuchi.2016.09.004_bib0325","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"15","key":"10.1016\/j.neuchi.2016.09.004_bib0330","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1 and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.neuchi.2016.09.004_bib0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"4","key":"10.1016\/j.neuchi.2016.09.004_bib0340","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"M mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"issue":"9861","key":"10.1016\/j.neuchi.2016.09.004_bib0345","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre randomised placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuchi.2016.09.004_bib0350","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.neuchi.2016.09.004_bib0355","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","article-title":"Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients","volume":"35","author":"Plotkin","year":"2014","journal-title":"Otol Neurotol"},{"issue":"21 (Suppl. 1)","key":"10.1016\/j.neuchi.2016.09.004_bib0360","first-page":"S33","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"Dombi","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuchi.2016.09.004_bib0365","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1259\/bjr.20160110","article-title":"Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment","volume":"89","author":"Morris","year":"2016","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.neuchi.2016.09.004_bib0370","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized flexible crossover double-blinded placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"Widemann","year":"2014","journal-title":"Neuro Oncol"}],"container-title":["Neurochirurgie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028377016301308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028377016301308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:29:55Z","timestamp":1758436195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028377016301308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0028377016301308"],"URL":"https:\/\/doi.org\/10.1016\/j.neuchi.2016.09.004","relation":{},"ISSN":["0028-3770"],"issn-type":[{"value":"0028-3770","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports","name":"articletitle","label":"Article Title"},{"value":"Neurochirurgie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuchi.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}